National, Multicenter, Randomized, Double-blind, Triple-dummy, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Berlim 25/20 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia.

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 21 Feb 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Berlim 25/20 association (Primary) ; Empagliflozin; Rosuvastatin
Indications Dyslipidaemias; Type 2 diabetes mellitus
Focus Registrational; Therapeutic Use
Sponsors EMS

Most Recent Events

15 Feb 2024 Status changed from not yet recruiting to recruiting.
03 Aug 2022 Planned End Date changed from 1 Feb 2024 to 1 Aug 2025.
03 Aug 2022 Planned primary completion date changed from 1 Nov 2023 to 1 Apr 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight